Journal of microencapsulation最新文献

{"title":"Alginate-based encapsulation of bioactive compounds from <i>Cannabis sativa</i> L. chemotype II: synthesis of microparticles, characterisation and <i>in vitro</i> release.","authors":"Luciano Protti Cosenza, Agustina Fernández, Maria Luisa Franchi, Alexander P Aguila Wharton, Luciana Mentasti, Gastón Barreto","doi":"10.1080/02652048.2026.2669793","DOIUrl":"10.1080/02652048.2026.2669793","url":null,"abstract":"<p><p>This study developed alginate-based microparticles (MPs) to encapsulate cannabis chemotype II bioactives as a strategy to overcome their low oral bioavailability. MPs were produced by ionic gelation/extrusion and coated with chitosan (CA-MPs) or pectin (PA-MPs) to modulate matrix integrity and release behaviour. Characterisation included stability, encapsulation efficiency (EE%), particle size, FTIR, SEM, and <i>in vitro</i> release in simulated gastrointestinal fluids. The optimised formulation (1.0% alginate, 0.1 M Ca²⁺) achieved high EE% (CBD 78.8 ± 0.9%; THC 46.5 ± 0.5% for CA-MPs) and high total cannabinoid content (up to 21.36% w/w). MPs exhibited monodisperse size distributions (PDI < 0.01). Stability tests demonstrated significant cannabinoid protection, although light exposure caused some degradation, especially for THC. Chitosan or pectin coatings increased particle size and modulated drug release, resulting in a three-phase pH-dependent profile with delayed release compared to uncoated MPs. Overall, alginate MPs with biopolymer coatings represent a promising oral delivery platform to enhance the stability and therapeutic efficacy of cannabis bioactives.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"867-883"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-assisted liquid antisolvent processing of curcumin-lecithin amorphous nanoparticles for enhanced dissolution and storage stability.","authors":"Anitarakhmi Handaratri, Bramantyo Airlangga, Firman Kurniawansyah, Cindy Mutiara Septani, Sumarno Sumarno","doi":"10.1080/02652048.2026.2669789","DOIUrl":"10.1080/02652048.2026.2669789","url":null,"abstract":"<p><p>This study aimed to develop amorphous curcumin nanoparticles using an ultrasound-assisted liquid antisolvent (UALA) process and to evaluate their physicochemical properties, dissolution behaviour, and storage stability. Curcumin-lecithin nanoparticles were prepared under varying sonication times and characterised using Fourier-transform infra-red (FTIR) spectroscopy, X-ray diffraction (XRD), thermal analysis, morphology analysis, wettability measurements, and dissolution testing. The optimised formulation (30 min sonication) produced fully amorphous core-shell particles with a mean diameter of 102.6 ± 3.1 nm, encapsulation efficiency of 70-90% w/w, and loading capacity of 10-15% w/w. UALA processing improved wettability (surface tension 27.9 ± 0.08 mN/m) and markedly enhanced dissolution, reaching 89.89% at 120 min compared with <2% for native curcumin. After 30 days, dissolution remained high (84.20%), demonstrating excellent stability. Overall, UALA enabled complete amorphization and significantly enhanced curcumin's dispersibility and release, offering a practical approach for functional food and pharmaceutical applications.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"834-845"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147930576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transdermal delivery of <i>Astragalus tomentosus</i> hyaluoleosomes assisted by hollow microneedles for managing rheumatoid arthritis: <i>in-vitro</i> evaluation and biological studies.","authors":"Mariam Zewail, Haidy Abbas, Nesrine El Sayed, Mohamed Fayez Dekinash, Reham Mustafa, Heba Abd- El-Azim","doi":"10.1080/02652048.2026.2669785","DOIUrl":"10.1080/02652048.2026.2669785","url":null,"abstract":"<p><strong>Aim: </strong>To develop and evaluate Astragalus tomentosus (AST)-loaded hyaluoleosomes delivered via hollow microneedles as a novel approach for rheumatoid arthritis (RA) management.</p><p><strong>Methods: </strong>AST-loaded hyaluoleosomes were prepared and characterized for particle size, polydispersity index, zeta potential, and <i>in vitro</i> drug release. The optimized formulation was intradermally administered using hollow microneedles in antigen-induced arthritis rats. Therapeutic efficacy was assessed by measuring inflammatory markers (TNF-α, IL-1, MMP-9), antioxidant markers (HO-1, NRF2, SOD), and histopathological changes.</p><p><strong>Results: </strong>The optimized formulation showed nanosized particles (∼217 nm), low PDI, and stable zeta potential, with sustained drug release over 96 h. <i>In vivo</i>, it significantly reduced joint swelling, suppressed inflammatory mediators, restored antioxidant markers, and improved histopathological features with reduced synovial inflammation and cartilage damage.</p><p><strong>Conclusion: </strong>AST-loaded hyaluoleosomes delivered via microneedles offer a minimally invasive and effective RA treatment, demonstrating synergistic therapeutic effects.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"802-819"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147930578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hyaluronic acid-functionalised solid lipid nanoparticles for enhanced oral uptake and therapeutic efficacy in rheumatoid arthritis.","authors":"Mangesh R Bhalekar, Ashwini R Madgulkar, Yogesh R Rewachandani, Vidhi Anil Dagade","doi":"10.1080/02652048.2026.2669791","DOIUrl":"10.1080/02652048.2026.2669791","url":null,"abstract":"<p><p>The aim of present work was to develop and optimise hyaluronic acid-functionalised, chloroquine-loaded solid lipid nanoparticles (HA-CQL-SLNs) for CD44 receptor-mediated therapy of rheumatoid arthritis. The Chloroquine base was precipitated and characterised using UV spectroscopy, FTIR, and DSC. Solid lipid nanoparticles were prepared by melt emulsification followed by probe sonication and optimised using a Box-Behnken design. Particle size, polydispersity index, zeta potential, and entrapment efficiency were evaluated. Ex vivo intestinal uptake was assessed using endocytosis inhibitors, while in vivo pharmacokinetic studies with cycloheximide pretreatment evaluated lymphatic transport. Therapeutic efficacy was studied in arthritic rats. The optimised HA-CQL-SLNs showed a particle size of 412.8 ± 0.71 nm, zeta potential of -9.6 ± 2.3 mV, and entrapment efficiency of 94.6 ± 0.49% (w/w). The lymphatic uptake involved clathrin- and caveolae-mediated endocytosis which was established by reduced systemic drug exposure in animals receiving Cycloheximide pre-treatment. HA-CQL-SLNs significantly reduced paw oedema and joint damage. Thus it can be concluded that HA-CQL-SLNs enhanced bioavailability and therapeutic efficacy, demonstrating potential as a targeted oral delivery system for rheumatoid arthritis.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"846-866"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147973142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the potential of Vitamin E: nanocolloidal-based topical delivery systems.","authors":"Drashti Shukla, Priyanka Uniyal, Vipin Saini, Devesh U Kapoor, Bhupendra G Prajapati, Omar Awad Alsaidan, Sami I Alzarea","doi":"10.1080/02652048.2026.2667729","DOIUrl":"10.1080/02652048.2026.2667729","url":null,"abstract":"<p><p>Vitamin E, a vital antioxidant, plays a key role in maintaining skin health by protecting cells from oxidative stress, reducing inflammation, and supporting moisture retention. This review highlights recent progress in colloidal delivery systems designed for the topical administration of Vitamin E. It explores advanced carriers including liposomes, solid lipid nanoparticles, nanoemulsions, and microemulsions that improve Vitamin E's stability, skin penetration, and bioavailability. These innovative systems help protect Vitamin E from environmental degradation and enable controlled, sustained release to prolong its therapeutic benefits. The review summarises current research findings, emerging trends, and practical applications in dermatology and skincare. It also outlines major challenges, such as poor stability and limited cutaneous absorption, and discusses how colloidal technologies can overcome these limitations. By consolidating existing evidence and identifying key knowledge gaps, this review encourages further investigation into optimised topical formulations that maximise the clinical and cosmetic potential of Vitamin E.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"753-774"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and evaluation of polymeric nanoparticles loaded gel for topical delivery of propranolol.","authors":"Zahoor Ul Haq, Hajra Afeera Hameed, Naveed Ahmed, Maria Awan","doi":"10.1080/02652048.2025.2611219","DOIUrl":"10.1080/02652048.2025.2611219","url":null,"abstract":"<p><p>Oral administration of Propranolol suffers from lower bioavailability due to high hepatic first pass metabolism. The study undertakes development of propranolol loaded polymeric nanoparticles, that was further loaded into gel matrix for topical application. The nanoparticles were prepared by precipitation-ultra-sonication method and were assessed for their physico chemical properties, morphology, drug release, and permeation analysis. The propranolol loaded nanoparticles had a particle size of 123 nm with polydispersity index of 0.111. The entrapment efficiency of nanoparticles was 85% with percentage yield of 67%. The SEM study showed particles size in the range of 115 nm to 150 nm with smooth & spherical surface morphology. The XRD analysis revealed that nanoparticles were amorphous in nature. The nanoparticles loaded gel have optimum pH, viscosity and spreadability for topical application. The gel matrix showed 83% propranolol release within 24 hours and followed Higuchi model. The permeation of drug from the gel was higher at skin pH of 5.5, depicting the suitability of fabricated gel for potential application in Infantile Haemangiomas.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"775-785"},"PeriodicalIF":3.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Polyurethane-based targeted active nanocarriers for colon cancer treatment.","authors":"Gamze Usta, Baki Hazer, Zeynep Karahaliloğlu","doi":"10.1080/02652048.2026.2667730","DOIUrl":"10.1080/02652048.2026.2667730","url":null,"abstract":"<p><p>This study aims to develop an alternative nanoparticle-based formulation for targeted colon cancer therapy. A biocompatible thermoplastic polyurethane-oleic acid-polyethylene glycol (TPU-OLE-PEG) copolymer was synthesised. Curcumin (CUR), a natural polyphenol, was loaded into the nanoparticles, followed by folate (FO) conjugation for enable targeted delivery to HT-29 colon adenocarcinoma cells. Optimised nanoparticles exhibited a spherical, homogeneous, and monodisperse morphology with an average size of 249 ± 5.7 nm, a zeta potential (ZP) of -28.9 ± 0.8 mV, and a polydispersity index (PDI) of 0.085. The drug loading efficiency exceeded 95%, while the folate conjugation efficiency reached 98.3%. <i>In vitro</i> release studies indicated sustained drug delivery over 19 days. Flow cytometry analysis revealed that CUR-loaded nanoparticles reduced HT-29 cell viability to 66.35%, and FO conjugation further decreased it to 52.74%. The FO-CUR-TPU-OLE-PEG nanoparticle system exhibits strong potential as a targeted therapeutic platform for colon cancer and represents a promising alternative to currently available formulations.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"786-801"},"PeriodicalIF":3.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147839021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PLGA-lecithin nanocarrier encapsulating curcuma caesia oil in a mucoadhesive gel: efficacy analysis against periodontal infections.","authors":"Bhabani Sankar Satapathy, Mahaprasad Mohanty, Sritam Behera","doi":"10.1080/02652048.2025.2531784","DOIUrl":"10.1080/02652048.2025.2531784","url":null,"abstract":"<p><strong>Aim: </strong>The study reported development of <i>Curcuma caesia</i> leaf essential oil encapsulated poly(lactic-co-glycolic acid) (PLGA) nanocarrier-embedded gel as a potential strategy to treat periodontal infection.</p><p><strong>Method: </strong>\u0000 <i>Curcuma caesia oil loaded experimental nanocarriers (CNCs) were developed by nano precipitation method and characterized. In vitro and in vivo efficacy of CNCs loaded gel (CNCsG) was evaluated.</i>\u0000 </p><p><strong>Results: </strong>GC/MS analysis revealed Borneol as the major phytoactive constituent. CNCs were spherical, nanosized (51.28 ± 2.1 nm), with -40.5 ± 0.8% mV surface charge, 20.8 ± 0.7% w/w oil loading and 86.4 ± 1.3% encapsulation efficiency. CNCsG was reported with satisfied mucoadhesion (45.66 ± 2.2 dyne/cm2), viscosity (37745 ± 32.7 cps), spreadability (6.5 ± 1.2 gm.cm/sec), sustained ex-vivo release. A faster recovery of infection towards normal was observed in periodontitis rats by CNCsG than Clorni gel. Improved plasma pharmacokinetic profile was reported for CNCsG as compared to standard gel.</p><p><strong>Conclusion: </strong>CNCsG was reported having promising antibacterial potency. <i>In vivo</i> efficacy data would lay foundation for futuristic clinical testing of CNCsG in periodontitis.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"702-720"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic anti-breast cancer activity of simvastatin and thymoquinone encapsulated in nanostructured lipid carriers for enhanced therapeutic outcomes.","authors":"Pallavi Kumari, Javed Ali, Sanjula Baboota, Amit Tyagi, Shweta Dang","doi":"10.1080/02652048.2025.2521077","DOIUrl":"10.1080/02652048.2025.2521077","url":null,"abstract":"<p><p>This study aims to study the combined anti-cancer effects of Simvastatin (SIM) and Thymoquinone (THY) against breast cancer cell lines and to develop and evaluate nanostructured lipid carriers (NLCs) encapsulating Simvastatin and Thymoquinone. Nanostructured lipid carriers (NLCs) co-loaded with Simvastatin and Thymoquinone were successfully formulated for enhanced anticancer activity. The formulations were characterised using Transmission Electron Microscopy (TEM), Scanning Electron Microscopy (SEM), and X-Ray Diffraction (XRD) to determine particle morphology and crystallinity. Key physicochemical parameters, including mean particle size, polydispersity index (PDI), zeta potential, and drug loading capacity, were systematically evaluated. Encapsulation efficiency and in vitro drug release profiles were assessed using the dialysis bag diffusion method, while formulation stability was monitored at 4 °C, 25 °C, and 40 °C over a defined period. In vitro biological evaluations were conducted on MCF-7 and MDA-MB-231 breast cancer cell lines. Cytotoxic potential was determined through MTT assay and IC50 value estimation. Cellular uptake was visualised using fluorescence microscopy, and apoptosis induction was quantified via flow cytometry using Annexin V-FITC/PI dual staining. The results suggest that the co-delivery of Simvastatin and Thymoquinone via NLCs enhances intracellular drug accumulation and promotes apoptosis, highlighting their potential as a synergistic nanocarrier-based therapy for breast cancer treatment. The optimised SIM-THY-NLCs were spherical with mean diameter of 105.6 ± 4.2 nm, PDI of 0.214 ± 0.03, and zeta potential of -28.6 ± 2.1 mV. Encapsulation efficiencies were 89 ± 1.59% (SIM) and 91 ± 1.45% (THY). Sustained drug release over 24 h was observed (SIM: 40%, THY: 65%). The NLCs showed significantly improved cytotoxicity with IC₅₀ values of 2.56 µg/ml (MCF-7) and 1.23 µg/ml (MDA-MB-231), alongside enhanced cellular uptake and apoptosis. SIM-THY-NLCs significantly improve drug stability, release, and anticancer efficacy on breast cancer cells establishing them as a promising nanocarrier system for effective breast cancer therapy.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"682-701"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced chitosan-based biopolymer systems for probiotic microencapsulation: stability enhancement and targeted release approaches.","authors":"Great Iruoghene Edo, Alice Njolke Mafe, Ali B M Ali, Emad Yousif, Raghda S Makia, Endurance Fegor Isoje, Ufuoma Augustina Igbuku, Patrick Othuke Akpoghelie, Joseph Oghenewogaga Owheruo, Rapheal Ajiri Opiti, Arthur Efeoghene Athan Essaghah, Dina S Ahmed, Huzaifa Umar","doi":"10.1080/02652048.2025.2531776","DOIUrl":"10.1080/02652048.2025.2531776","url":null,"abstract":"<p><strong>Context: </strong>Probiotic microencapsulation is an advanced technique designed to protect live probiotic microorganisms by enclosing them within a protective matrix, typically composed of biocompatible biopolymers.</p><p><strong>Objective: </strong>This review provides a comprehensive analysis of recent advancements in bio-polymer coatings for probiotic microencapsulation, with a focus on chitosan and its synergistic combinations with other materials.</p><p><strong>Methods: </strong>This methods highlights the necessity for continued innovation in bio-polymer coatings, emphasizing the development of bio-responsive materials, AI-driven formulation strategies, and next-generation encapsulation technologies to meet the evolving demands of functional foods and precision therapeutics.</p><p><strong>Results: </strong>Probiotic microencapsulation plays a critical role in protecting probiotics from environmental stresses, improving stability, and ensuring targeted delivery. Innovations in chitosan-based encapsulation, including its combination with bio-polymers such as alginate, gelatin, and pectin, have enhanced encapsulation efficiency, controlled release, and probiotic viability. Cutting-edge techniques such as nanotechnology, stimuli-responsive coatings, and hybrid bio-polymers are explored for their potential to optimize probiotic performance in food and pharmaceutical applications.</p><p><strong>Conclusions: </strong>Despite these advancements, obstacles remain in ensuring consistent release profiles, mitigating the inhibitory effects of chitosan on certain probiotic strains, and optimizing large-scale production while maintaining cost-effectiveness. The need for personalized probiotic therapies has driven research into adaptive encapsulation systems tailored to individual gut microbiota compositions.</p>","PeriodicalId":16391,"journal":{"name":"Journal of microencapsulation","volume":" ","pages":"635-659"},"PeriodicalIF":3.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}